Inotersen Treatment for Patients With Hereditary Transthyretin Amyloidosis | oneAMYLOIDOSISvoice
Scientific Articles

Inotersen Treatment for Patients With Hereditary Transthyretin Amyloidosis

key information

source: The New England Journal of Medicine

year: 2018

authors: Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T

summary/abstract:

Background:

Hereditary transthyretin amyloidosis is caused by pathogenic single-nucleotide variants in the gene encoding transthyretin ( TTR) that induce transthyretin misfolding and systemic deposition of amyloid. Progressive amyloid accumulation leads to multiorgan dysfunction and death. Inotersen, a 2′- O-methoxyethyl-modified antisense oligonucleotide, inhibits hepatic production of transthyretin.

Methods:

We conducted an international, randomized, double-blind, placebo-controlled, 15-month, phase 3 trial of inotersen in adults with stage 1 (patient is ambulatory) or stage 2 (patient is ambulatory with assistance) hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomly assigned, in a 2:1 ratio, to receive weekly subcutaneous injections of inotersen (300 mg) or placebo. The primary end points were the change in the modified Neuropathy Impairment Score+7 (mNIS+7; range, -22.3 to 346.3, with higher scores indicating poorer function; minimal clinically meaningful change, 2 points) and the change in the score on the patient-reported Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire (range, -4 to 136, with higher scores indicating poorer quality of life). A decrease in scores indicated improvement.

Results:

A total of 172 patients (112 in the inotersen group and 60 in the placebo group) received at least one dose of a trial regimen, and 139 (81%) completed the intervention period. Both primary efficacy assessments favored inotersen: the difference in the least-squares mean change from baseline to week 66 between the two groups (inotersen minus placebo) was -19.7 points (95% confidence interval [CI], -26.4 to -13.0; P<0.001) for the mNIS+7 and -11.7 points (95% CI, -18.3 to -5.1; P<0.001) for the Norfolk QOL-DN score. These improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy. There were five deaths in the inotersen group and none in the placebo group. The most frequent serious adverse events in the inotersen group were glomerulonephritis (in 3 patients [3%]) and thrombocytopenia (in 3 patients [3%]), with one death associated with one of the cases of grade 4 thrombocytopenia. Thereafter, all patients received enhanced monitoring.

Conclusions:

Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephritis were managed with enhanced monitoring.

organization: Indiana University School of Medicine, USA; Federal University of Rio de Janeiro, USA; Harvard Medical School, USA; Johns Hopkins University, USA; Mayo Clinic, USA; University of California, USA; Université Paris Est, France; Institute for Neurologic Research Raúl Carrea, Argentina; University of Pavia, Italy; Hospital AACD (Associação de Assistência à Criança Deficiente), Brazil; Columbia University Medical Center and Mount Sinai Medical Center, USA; University College London-National Amyloidosis Centre, UK; University of Pennsylvania Health System, USA; Centre Hospitaliere Universitaire Bicêtre, AP-HP, France; Oregon Health and Science University, USA; Centro Hospitalar Lisboa Norte-Hospital de Santa Maria, Portugal; Centro Hospitalar do Porto, Portugal; Universitätsklinikum Münster, Germany; Universitat de Barcelona, Spain; Hospital Universitari Vall d'Hebron, Spain; Auckland City Hospital, New Zealand; Ionis Pharmaceuticals, USA

DOI: 10.1056/NEJMoa1716793

read more full text source

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close